ProQR Therapeutics (PRQR) Receivables - Net (2022 - 2026)

ProQR Therapeutics (PRQR) has reported Receivables - Net for 4 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables - Net changed N/A year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (changed N/A YoY) and the FY2025 annual result came in at $7.7 million, up 81.48% from the prior year.
• Receivables - Net slipped to $5.0 million in Q1 2026 per PRQR's latest filing, from $7.7 million in the prior quarter.
• Over the last five years, Receivables - Net for PRQR reached as high as $64.0 million in Q4 2022 and fell as low as $4.3 million in Q4 2024.
• A 4-year average of $20.3 million and a median of $6.4 million in 2025 frame the typical range for Receivables - Net.
• The largest YoY upside for Receivables - Net was 81.48% in 2025 against a maximum downside of 81.48% in 2025.
• Year by year, Receivables - Net stood at $64.0 million in 2022, then slumped by 93.34% to $4.3 million in 2024, then soared by 81.48% to $7.7 million in 2025, then plunged by 35.24% to $5.0 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $5.0 million, $7.7 million, and $4.3 million for Q1 2026, Q4 2025, and Q4 2024 respectively.